US2020071328A1PendingUtilityA1
1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
Est. expiryAug 25, 2032(~6.1 yrs left)· nominal 20-yr term from priority
Inventors:Vijaykumar Jagdishwar PatilRavikumar TadiparthiBharat DondAmol KaleLoganathan VelupillaiDeepak DekhaneSatish BirajdarMohammad Usman ShaikhSushilkumar MauryaPiyush Ambalal PatelPrasad DixitMangesh PawarMahesh Vithalbhai PatelSachin Bhagwat
A61K 31/4545C07C 211/63A61K 31/55A61K 31/439A61K 9/0053C07D 487/08C07D 471/08A61K 31/496A61K 9/20A61K 31/546A61K 45/06A61P 31/04A61K 9/48A61K 31/407
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical composition, comprising: (a) at least one antibacterial agent independently selected from cefpodoxime, ceftibuten, cefuroxime, cefixime and pharmaceutically acceptable salts thereof; and (b) at least one compound independently selected from:
and
stereoisomers and pharmaceutically acceptable salts thereof.
2 . The pharmaceutical composition of claim 1 , further comprising at least one pharmaceutically acceptable excipient.
3 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is cefpodoxime or a pharmaceutically acceptable salt thereof.
4 . The pharmaceutical composition of claim 3 , wherein the cefpodoxime is cefpodoxime axetil.
5 . The pharmaceutical composition of claim 3 , wherein the cefpodoxime is cefpodoxime proxetil.
6 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is ceftibuten or a pharmaceutically acceptable salt thereof.
7 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is cefuroxime or a pharmaceutically acceptable salt thereof.
8 . The pharmaceutical composition of claim 7 , where the cefuroxime is cefuroxime axetil.
9 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is cefiximeor a pharmaceutically acceptable salt thereof.
10 . The pharmaceutical composition of claim 1 , wherein the at least one compound is in the form of a sodium salt.
11 . The pharmaceutical composition of claim 1 , wherein the at least one compound is
or a stereoisomer or pharmaceutically acceptable salt thereof.
12 . The pharmaceutical composition of claim 1 , wherein the at least one compound is
or a stereoisomer or pharmaceutically acceptable salt thereof.
13 . The pharmaceutical composition of claim 1 , wherein the at least one compound is
or a stereoisomer or pharmaceutically acceptable salt thereof.
14 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is cefpodoxime, and the at least one compound is
15 . The pharmaceutical composition of claim 14 , wherein the cefpodoxime is cefpodoxime axetil.
16 . The pharmaceutical composition of claim 14 , wherein the cefpodoxime is cefpodoxime proxetil.
17 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is ceftibuten, and the at least one compound is
18 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is cefuroxime, and the at least one compound is
19 . The pharmaceutical composition of claim 18 , wherein the cefuroxime is cefuroxime axetil.
20 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is cefixime, and the at least one compound isJoin the waitlist — get patent alerts
Track US2020071328A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.